Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

59.87 -0.26 (-0.43%)

Streaming Delayed Price Updated: 2:06 PM EDT, Mar 11, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	4,307,169
Open	60.00
Bid (Size)	59.85 (300)
Ask (Size)	59.89 (900)
Prev. Close	60.13
Today's Range	59.27 - 60.03
52wk Range	42.52 - 63.33
Shares Outstanding	2,222,113,553
Dividend Yield	4.21%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

BioNTech Navigates Post-Pandemic Deficit: A €17 Billion Bet on the Oncology Frontier

March 10, 2026

In a watershed moment for the biotechnology sector, BioNTech SE (NASDAQ: BNTX) has reported its full-year 2025 financial results, signaling the definitive end of the COVID-19 vaccine gold rush and the...

Via MarketMinute

3 Healthcare Stocks Paying the Highest Dividends of 2026 ↗

March 10, 2026

A handful of the industry's income-generating gems are hiding in plain sight.

Via The Motley Fool

Performance

YTD	+12.0%	+12.0%
1 Month	-1.5%	-1.5%
3 Month	+18.2%	+18.2%
6 Month	+26.8%	+26.8%
1 Year	-5.1%	-5.1%

More News

Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

March 09, 2026

From Bristol Myers Squibb

Via Business Wire

Why Bristol Myers Squibb Stock Crushed it in February ↗

March 08, 2026

Via The Motley Fool

U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis

March 06, 2026

From Bristol Myers Squibb

Via Business Wire

2 Top Healthcare Dividend Stocks to Buy and Hold Forever ↗

March 05, 2026

Via The Motley Fool

Q4 Earnings Outperformers: Bristol-Myers Squibb (NYSE:BMY) And The Rest Of The Branded Pharmaceuticals Stocks

March 04, 2026

Via StockStory

IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook ↗

March 03, 2026

Via Stocktwits

Bristol Myers Squibb Announces Dividend

March 02, 2026

From Bristol Myers Squibb

Via Business Wire

How to Spot Winning Innovation ↗

March 02, 2026

Via The Motley Fool

FourWorld Takes a Major Swing on Sable Offshore (SOC), Buying 8 Million Shares ↗

March 02, 2026

Via The Motley Fool

Big Pharma Dividend Stock BMY Could Help Turn $100,000 Into a Seven‑Figure Retirement ↗

February 28, 2026

Via The Motley Fool

Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy

February 26, 2026

Via MarketMinute

SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

February 26, 2026

From Bristol Myers Squibb

Via Business Wire

Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics

February 25, 2026

Via MarketMinute

Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity

February 24, 2026

Via FinancialNewsMedia

3 Reasons to Avoid BMY and 1 Stock to Buy Instead

February 23, 2026

Via StockStory

Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference

February 23, 2026

From Bristol Myers Squibb

Via Business Wire

European Commission Grants Marketing Authorization to Cytokinetics for Cardiac Drug MYQORZO

February 23, 2026

Via MarketMinute

Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia

February 23, 2026

From Bristol Myers Squibb

Via Business Wire

2 Large-Cap Stocks on Our Buy List and 1 That Underwhelm

February 22, 2026

Via StockStory

Down 25%, Should You Buy the Dip on Bristol Myers Squibb? ↗

February 21, 2026

Via The Motley Fool

2 Incredibly Cheap Dividend Stocks to Buy Now ↗

February 19, 2026

Via The Motley Fool

3 Stocks to Buy and Hold for 2026 and Beyond ↗

February 19, 2026

Via The Motley Fool

Cytokinetics Secures Triple Crown: EU Approval of MYQORZO Solidifies Global Reach in Cardiovascular Market

February 19, 2026

Via MarketMinute

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?

Yes, Bristol-Myers Squibb is publicly traded.

What exchange does Bristol-Myers Squibb trade on?

Bristol-Myers Squibb trades on the New York Stock Exchange

What is the ticker symbol for Bristol-Myers Squibb?

The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange

What is the current price of Bristol-Myers Squibb?

The current price of Bristol-Myers Squibb is 59.87

When was Bristol-Myers Squibb last traded?

The last trade of Bristol-Myers Squibb was at 03/11/26 02:06 PM ET

What is the market capitalization of Bristol-Myers Squibb?

The market capitalization of Bristol-Myers Squibb is 133.04B

How many shares of Bristol-Myers Squibb are outstanding?

Bristol-Myers Squibb has 133B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.